ERCC1 and personalized medicine in lung cancer

Jeong Seon Ryu, Azra Memon, Seul-Ki Lee


Excision repair cross-complementing group 1 (ERCC1) is known to be a key player in nucleotide excision repair (NER) pathway. Its prognostic or predictive relevance has been extensively investigated in cancer patients including non-small-cell lung cancer. However, several questions should be addressed before its clinical application as biomarker for patient classification or guiding platinum treatment.